

Munich, 02nd May 2017

Press release

terrapiasma medical successfully completed financing

In March 2017, the Munich medical technology company terrapiasma medical GmbH successfully completed its first round of financing (seed). Several private investors with a great deal of industry experience are jointly providing the company with a mid-seven-digit EUR sum. The aim of this financing round is to enable the development and market approval of the plasma care, the world's first mobile, battery-powered medical device for the in-patient and out-patient treatment of chronic and acute wounds with cold plasma, which kills even multi-resistant germs and bacteria.

Multi-resistant germs and bacteria are one of the biggest problems in poorly healing chronic and acute wounds. terrapiasma medical takes responsibility for this problem towards society and has the vision to optimize the wound treatment process, to support the medical staff in the treatment and to Reduce pain in patients and thus improve their quality of life.

In order to achieve this vision, terrapiasma medical is developing a mobile, battery-operated medical device for inpatient and outpatient treatment of chronic and acute wounds, which uses cold plasma to kill even multi-resistant germs and bacteria. Plasma is often referred to as the 4th state of aggregation (after solid, liquid and gaseous) and describes a particle mixture whose components are partially charged components.

In a multi-centre clinical study led by the University Hospital Regensburg and the Munich Schwabing Clinic, in cooperation with Prof. Dr. Gregor Morfill and PD Dr. Julia Zimmermann treated over 300 patients and the bactericidal effect of cold plasmas in chronic and acute wounds on patients could be proven.

The lead investor of the group of investors, which consists of investors with a lot of industry experience, including from the Business Angels Region Stuttgart (BARS) and from the Munich area, is Fabian v. Kuenheim. "We are thrilled to have gained such an experienced and extraordinarily well-connected group of investors so that we can now implement our vision of innovative wound treatment with cold plasma in a targeted manner," says Jens Kirsch, Managing Director of terrapiasma medical, about the successful round of financing.

As part of this financing round, an advisory board was set up, chaired by Fabian v. Kuenheim: "I am very much looking forward to working with the experienced management team around the managing

directors Ms. PD Dr. Julia Zimmermann and Mr. Jens Kirsch in the development, market approval and clinical validation of this exciting and revolutionary technology in wound treatment.”

Further information under www.terraplasma-medical.com

Contact:

Jens Kirsch
Lichtenbergstraße 8
85748 Garching b. München
Deutschland
Office +49 (0)89 7167 7957-0
Fax +49 (0)89 7167 7957-9
E-Mail: jens.kirsch@terraplasma-medical.com

About Kuenheim Familiaris GmbH

Kuenheim Familiaris GmbH is the private investment company of the family of Fabian v. Kuenheim. Fabian v. Kuenheim was co-founder, largest shareholder and chairman of the board of Magirus AG, which he successfully sold to Avnet Inc. Through Kuenheim Familiaris GmbH, Fabian v. Kuenheim, also in the context of syndicated investor groups from his network, in high-tech companies in the areas of IT infrastructure and cloud computing, photonics, med tech, mobility and integrated mobile systems as well as in companies that operate at the interfaces of these technology areas.

Contact:

Fabian v. Kuenheim
Kuenheim Familiaris GmbH
Eichwiesenring 9
70567 Stuttgart
Deutschland
Office +49-(711)-720770-11
Fax +49-(711)-720770-10
E-Mail: fabian@kuenheim.com